| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2114907 | Cancer Letters | 2008 | 9 Pages |
Abstract
We studied by real-time PCR cyclin D1 and thymidylate synthase (TS) mRNA in plasma as possible markers of clinical outcome in breast cancer. We observed poor outcome in patients with presence of cyclin D1 mRNA in good-prognosis groups, such as negative vascular invasion. Presence of both markers was associated with non-response to treatment after relapse. In patients treated with tamoxifen, a trend to significant relation between poor outcome and cyclin D1 mRNA was found. Cyclin D1 mRNA in plasma could identify patients with poor overall survival in good-prognosis groups and patients non-responsive to tamoxifen.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Vanesa García, José M. García, Cristina Peña, Javier Silva, Gemma Domínguez, Yolanda Lorenzo, Raquel Diaz, Pablo Espinosa, Javier García de Sola, Blanca Cantos, Félix Bonilla,